Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bispecific antibodies
Pharma
J&J's Rybrevant moves into first line in lung cancer subtype
While Takeda's Exkivity is out of the picture, ArriVent BioPharma and AstraZeneca spinout Dizal are each working on EGFR lung cancer meds.
Angus Liu
Mar 4, 2024 11:13am
ASH: Roche offers glimpse at Columvi-Polivy combo in DLBCL
Dec 11, 2023 7:00am
AstraZeneca, Takeda, BioNTech—Fierce Pharma Asia
Nov 10, 2023 8:05am
J&J notches Rybrevant trial win as Tagrisso showdown nears
Sep 6, 2023 11:35am
J&J's myeloma bispecific not slowing Carvykti down: Legend exec
Aug 16, 2023 12:56pm
Pfizer brings multiple myeloma battle to J&J with new FDA nod
Aug 14, 2023 2:28pm